# Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine

> **NCT01118273** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 162 (actual)

## Conditions studied

- Sleep

## Interventions

- **DRUG:** Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg
- **DRUG:** Naproxen Sodium 440 mg (BAYH6689)
- **DRUG:** Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
- **DRUG:** Naproxen Sodium 220 mg (BAYH6689)
- **DRUG:** DPH 50mg
- **DRUG:** Ibuprofen 400 mg / Diphenhydramine citrate 76 mg

## Key facts

- **NCT ID:** NCT01118273
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118273, "Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01118273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*